Based on this earnings call transcript, I anticipate a positive short-term impact on UnitedHealth Group's stock price. Key positives include strong Q3 results with 12% revenue growth and 28% EPS growth, raised full-year guidance, optimistic commentary about 2019 growth prospects across multiple business segments, and solid fundamentals in their core businesses. Management exhibited confidence in maintaining their long-term 13-16% earnings growth target. While there are some minor headwinds like national accounts enrollment pressure, the overall tone was decidedly positive with strong momentum heading into 2019.

[1]